Bios+: Atty. Gabriele Gendotti appointed president
Institute of Oncology Research
The annual meeting of the Association of Bellinzona Scientific Institutes (Bios+), comprising the Institute for Research in Biomedicine (IRB) and the Oncology Research Institute (IOR), both affiliated with the University of Lugano (USI), took place on 4 June in Bellinzona. During the meeting, atty. Gabriele Gendotti was appointed as the new President for the next two years. In line with the Association's Articles of Association, which call for a change in presidency every two years, Prof. Franco Cavalli will now assume the role of Vice-President.
Under Prof. Cavalli's leadership, the biomedical hub in Bellinzona has continued to grow, with nearly 300 researchers now working in the Via Chiesa building. Progress has also been made in coordinating management activities between the IRB and IOR, alongside the development of several joint scientific projects. Among these, a significant initiative focused on age-related diseases stands out. This project, which could receive funding through the NCCR programme of FNRS, involves not only IRB and IOR but also USI, ETH Zurich, and other leading Swiss institutes. Currently under evaluation by SEFRI in Bern, the project has strong prospects for approval. If successful, it would mark a historic first for Ticino and provide significant momentum for research development in the region.
Over the next two years, under the leadership of Atty. Gabriele Gendotti , Bios+ will continue to promote innovation and scientific excellence both nationally and internationally, while advancing all ongoing and planned projects.
Meanwhile, Prof. Franco Cavalli, in his capacity as President of the IOR, will continue to lead the planning of a new building that will support the future growth of the institutes active in Bellinzona. The IOR Foundation has entrusted the architects Santer-Buzzi, winners of the recent competition, with the mandate to prepare the master plan, which is scheduled to be developed over the course of 2025.
